glp1
Rybelsus (semaglutide) tracker
Educational reference for Rybelsus (semaglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
165 h
Tmax
1 h
Category
glp1
Also known as: oral-semaglutide
Rybelsus is the oral tablet form of semaglutide, FDA-approved for type 2 diabetes. Taken orally.
Mechanism
Rybelsus is a brand name for oral semaglutide, a GLP-1 receptor agonist. See the semaglutide entry for the full mechanism.
Research summary
Rybelsus is the oral tablet formulation of semaglutide approved for type 2 diabetes (PIONEER program). See the semaglutide entry for broader context.
Reported side effects
As a semaglutide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the semaglutide entry. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Rybelsus prescribing information / PIONEER program · FDA prescribing information (2019)available via DailyMed; see semaglutide entry
TrackPep slouží ke sledování záznamů. Zaznamenává, co zadáte, a nikdy nedoporučuje ani nevypočítává množství.